1 on our Review article (Watts, G. et al. Demystifying the management of hypertriglyceridaemia. Nat. Rev. Cardiol. 10, 648-661 [2013]), 2 and would like to make the following observations. Hypertriglyceridaemia is a common risk factor for atherosclerotic cardiovascular disease (CVD). In our Review, we focused on contemporary guidance on managing hypertriglyceridaemia for preventing and treating atherosclerotic CVD, with an emphasis on established and novel treatments. Curcuminoids, a major natural component of turmeric, has been associated with a wide range of health benefits attributable to their anti-inflammatory, anti tumour, and antioxidant properties. However, the effect of curcuminoid supplementation on plasma lipid levels has not been extensively investigated. A meta-analysi s of five randomized, controlled studies by Dr Sahebkar did not show a significant effect of curcuminoid sup plementation on the serum triglyceride concentration, with a mean change of -1.29 mg/dl (range -9.05 to 6.46 mg/dl; P = 0.750). Another short-term (7-day) study showed that a low dose of curcuminoid supplementation (0.5 g daily) decreased the serum trigly ceride concentration by 47%, whereas a high dose (6 g daily) only decreased the serum triglyceride concentration by 15%.
CORRESPONDENCE
We appreciate the letter by Dr Sahebkar (Curcuminoids for the management of hypertriglyceridaemia. Nat. Rev. Cardiol. doi:10.1038 /nrcardio.2013 1 on our Review article (Watts, G. et al. Demystifying the management of hypertriglyceridaemia. Nat. Rev. Cardiol. 10, 648-661 [2013] ), 2 and would like to make the following observations. Hypertriglyceridaemia is a common risk factor for atherosclerotic cardiovascular disease (CVD). In our Review, we focused on contemporary guidance on managing hypertriglyceridaemia for preventing and treating atherosclerotic CVD, with an emphasis on established and novel treatments. Curcuminoids, a major natural component of turmeric, has been associated with a wide range of health benefits attributable to their anti-inflammatory, anti tumour, and antioxidant properties. However, the effect of curcuminoid supplementation on plasma lipid levels has not been extensively investigated. A meta-analysi s of five randomized, controlled studies by Dr Sahebkar did not show a significant effect of curcuminoid sup plementation on the serum triglyceride concentration, with a mean change of -1.29 mg/dl (range -9.05 to 6.46 mg/dl; P = 0.750). Another short-term (7-day) study showed that a low dose of curcuminoid supplementation (0.5 g daily) decreased the serum trigly ceride concentration by 47%, whereas a high dose (6 g daily) only decreased the serum triglyceride concentration by 15%.
5
DiSilvestro et al. demonstrated that a low dose of lapidated curcumin (0.8 g daily) modestly decreased the plasma triglyceride concentration by 10%.
6 Na et al. found that a low dose of curcuminoid supplementation (0.3 g daily for 3 months) decreased the serum triglyceride concentration by 17%.
7 Notably, in the majority of studies, the effect of curcuminoid supplementation was examined in individuals with normal triglyceride levels.
Taken together, no definitive evidence exists to support the use of curcumin oid supplementation to treat patients with hypertriglyceridaemia. Therefore, we consider that more research is required before deriving any recommendations on the clinical use of curcuminoids in the management of hypertriglyceridaemia. Studies of the effects of curcuminoid supplement ation, alone or in combination with a statin, on postprandial lipaemia and other surrogate markers of the metabolism of trigly ceriderich lipoprotein (such as apolipo protein [apo] B-48, apoB-100, apoC-III, and remnant-like particle-cholesterol) also merit investigation. 
